# Molecular Diagnostics for Transplant Market

> Molecular Diagnostics for Transplant Market Research Report Information by Product (Reagents & Kits, Instruments, and Services & Software), by Technology (Polymerase Chain Reaction (PCR), Sequencing, Microarray, and Others), by End User (Hospitals and Transplant Centers, Research Laboratories & Academic Institutes, and Others), and By Region (North America, Europe, Asia-Pacific, And Rest of The World) - Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.91%
- **2024:** $ 0.84 Billion
- **2025:** $ 0.92 Billion
- **2035:** $ 2.15 Billion
- **Key Players:** Thermo Fisher Scientific (US), Roche Diagnostics (CH), Abbott Laboratories (US), Qiagen (DE), Hologic (US), Becton Dickinson (US), Genomic Health (US), Myriad Genetics (US), Illumina (US)

**Report ID:** MRFR/MED/10305-CR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/molecular-diagnostics-for-transplant-market-11826

---

## Market Summary

## **Global Molecular Diagnostics for Transplant Market Overview**

Molecular Diagnostics for Transplant Market size was valued at USD 0.66 billion in 2021. The Molecular Diagnostics for Transplant Market industry is projected to grow from USD 0.71 billion in 2022 to USD 1.40 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.91% during the forecast period (2024 - 2030).

Increasing prevalence of infectious diseases, rising number of transplant procedures, and advancements in molecular diagnostic techniques are bolstering the market growth.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **Molecular Diagnostics for Transplant Market Trends**

There has been an increasing prevalence of infectious diseases owing to various factors such as climate change, rapid urbanization, microbial evolution, among others. Special care needs to be taken before transplantation as a transplant patient can get any type of infection caused by bacteria, viruses, fungi and parasites. These include influenza virus infection, urinary tract infection, pneumococcal pneumonia, Cytomegalovirus, Epstein-Barr virus, Human herpesvirus 6, among several others. Moreover, increasing antimicrobial resistance is also a cause of serious concern and has been adding to the increasing prevalence of infectious disease.

For instance, according to the Centers for Disease Control and Prevention, more than 2.8 million antimicrobial-resistant infections occur in the US each year. Thus, increasing prevalence of infectious disease has driven the demand for implementation of thorough molecular diagnostics in transplantation, thereby, driving the market.

Moreover, the number of patients suffering from various types of cancers such as lung, blood, breast, and liver is increasing worldwide. In 2020, according to GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer (IARC), an estimated number of 19.3 million new cancer cases and about 10 million cancer deaths occurred globally.

Hence, the growing number of cancer patients and rising incidences of infectious diseases are increasing the demand for organ transplantation.

## **Molecular Diagnostics for Transplant Market Segment Insights**

### **Molecular Diagnostics for Transplant Product Insights**

The Molecular Diagnostics for Transplant Market segmentation, based on product, includes reagents & kits, instruments, and services & software. The reagents & kits segment held the largest market in 2021, with a market share of 42.77%, and is expected to register the highest CAGR from 2022 to 2030. Molecular diagnostic reagents include disease-specific kits and standard reagents that are used during infectious disease diagnosis and pathogen screening. Laboratory technicians utilize specific disease diagnostic kits for earlier and more precise identification of specific pathogen strains in a patient sample.

Standard reagents are key components of the majority of conventional molecular diagnostic procedures. Therefore, companies are now launching rapid reagents & kits to detect the novel coronavirus to fuel the growth of this market.

**March 2022** Immucor, Inc. (US) launched innovative transplant diagnostics MIA FORA NGS EXPRESS HLA Typing Software in order to provide a faster and easier NGS analysis experience.

### **Molecular Diagnostics for Transplant Technology Insights**

The Molecular Diagnostics for Transplant Market data has been segmented, based on technology, by polymerase chain reaction (PCR), sequencing, microarray, and others. The polymerase chain reaction (PCR) segment held the largest market in 2021, with a market share of ~35%, reaching a market value of around 0.5 billion by 2030. The sequencing segment is expected to register the highest CAGR of 10.59% from 2022 to 2030. Polymerase Chain Reaction (PCR) technology is used to identify a disease by analyzing the genetic and proteomic parameters such as deoxyribonucleic acid (DNA), and ribonucleic acid (RNA) in humans or the case of infections.

Additionally, it plays a crucial role in disease diagnostics and is considered to be one of the most developed molecular techniques which have a wide range of applications in the medicine field and for broad-spectrum pathogen detection and evaluation of emerging novel infections and surveillance.

October 2022: Eurobio Scientific (France) acquired Genome Diagnostics B.V. (Netherlands) for the commercial portfolio of human leukocyte antigen (HLA) diagnostics to assess the compatibility between donors and recipients for organ and marrow transplants.

**Figure 2: Molecular Diagnostics for Transplant Market, by Technology, 2023 & 2030 (USD Billion)**

****

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **Molecular Diagnostics for Transplant End User Insights**

Based on end user, the global molecular diagnostics for transplant industry has been segmented into the hospitals and transplant centers, research laboratories & academic institutes, and others. The hospitals and transplant centers segment held the largest market in 2021 and is expected to register the highest CAGR of 9.73% from 2022 to 2030. Hospitals and transplant centers witness significant growth due to the rising demand for novel tissue transplantation for treating organ failure, increasing demand for transplant products like tissue products, immunosuppressants, organ preservation solutions, and technological advancements.

Healthcare-associated infections  (HAIs) occur in all settings of care, such as ambulatory clinics, hospitals as well as nursing homes, and rehabilitation facilities.

### **Molecular Diagnostics for Transplant Regional Insights**

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America molecular diagnostics for transplant market accounted for the largest market share in 2021, due to rising demand technology evolution and increasing incidences of chronic diseases that lead to an increase in organ transplants. According to research, the number of kidneys, liver, heart, lung, pancreas, and intestine transplants is increasing in the US, while the number of kidney transplants is increasing in Canada.

Further, the major countries studied are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 3: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%)  BY REGION 2023**

****

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Europe molecular diagnostics for transplant market accounts for the second-largest market share owing to the rising prevalence of chronic diseases, including kidney, cardiovascular diseases (CVD), and respiratory diseases. Advancements in molecular diagnostics have improved the identification and understanding of specific gene defects for the appropriate organ transplant in kidney, heart, and lung failure. CVD diseases are influenced by factors such as atherosclerosis, blood clots, diabetes, a sedentary lifestyle, and obesity, which may lead to cardiac failure. In 2019, the European Society of Cardiology (ESC) Atlas estimated that Europe reports 11 million new cases suffering from CVD each year.

Furthermore, the Germany molecular diagnostics for transplant market held the largest market share, and the UK molecular diagnostics for transplant market was the second largest to hold the market share in the Europe region.

The Asia-Pacific molecular diagnostics for transplant market is expected to grow at a significant share from 2022 to 2030. The region's growing geriatric population demands organ transplantation, which may vary as per organ failure. In 2020, according to the World Economic Forum, China, India, and Japan had the oldest populations globally. Furthermore, it has been estimated that by 2050, one in four aged people will be living in the region. Moreover, China molecular diagnostics for transplant market held the largest market share, and the India molecular diagnostics for transplant market was the fastest growing market in the Asia-Pacific region.

**Molecular Diagnostics for Transplant Key Market Players & Competitive Insights**

Major market players are spending a lot of money on R&D to increase their product lines, which will help the molecular diagnostics for transplant market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the molecular diagnostics for transplant industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Thermo Fisher Scientific Inc. (US) specializes in various biotechnology products such as analytical instruments, laboratory supply chain programs and e-commerce, laboratory equipment, lab services, and specialty diagnostics. The company helps its customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to the market, and increase the laboratory's productivity. In September 2021, the company announced a new addition to its transplant diagnostics portfolio (a rapid next-generation sequencing assay that will provide high-resolution data in five hours). This new product enabled transplant laboratories to characterize samples better and bring speed and confidence to the transplant laboratory.

**Key Companies in the Molecular Diagnostics for Transplant Market includes.**

**Molecular Diagnostics for Transplant Industry Developments**

**October 2022** Eurobio Scientific (France) acquired Genome Diagnostics B.V. (Netherlands) for the commercial portfolio of human leukocyte antigen (HLA) diagnostics to assess the compatibility between donors and recipients for organ and marrow transplants.

**February 2022** Bio-Techne Corporation (US) entered into an agreement with Thermo Fisher Scientific, Inc. (US) in order to develop and commercialize the ExoTRU Kidney Transplant Rejection Test.

**In September 2021** Thermo Fisher Scientific Inc. (US) announced a new addition to its transplant diagnostics portfolio (a rapid next-generation sequencing assay that will provide high-resolution data in five hours). This new product enabled transplant laboratories to characterize samples better and bring speed and confidence to the transplant laboratory.

## **Molecular Diagnostics for Transplant Market Segmentation**

### **Molecular Diagnostics for Transplant Product Outlook**

### **Molecular Diagnostics for Transplant Technology Outlook**

### **Molecular Diagnostics for Transplant End User Outlook**

### **Molecular Diagnostics for Transplant Regional Outlook**

## Market Drivers

### Advancements in Genomic Technologies

Technological innovations in genomic sequencing and analysis are revolutionizing the Molecular Diagnostics for Transplant Market. The advent of next-generation sequencing (NGS) allows for comprehensive genetic profiling of both donors and recipients, enhancing the precision of transplant matching. This capability not only improves the likelihood of transplant success but also reduces the risk of rejection. Market data indicates that the NGS segment is expected to grow at a substantial rate, reflecting the increasing reliance on advanced molecular techniques in transplant diagnostics. Such advancements are likely to foster a more personalized approach to transplantation, aligning with the broader trends in healthcare.

### Rising Demand for Personalized Medicine

The shift towards personalized medicine is significantly impacting the Molecular Diagnostics for Transplant Market. As healthcare moves away from a one-size-fits-all approach, there is an increasing emphasis on tailoring treatments to individual patient profiles. Molecular diagnostics play a pivotal role in this paradigm shift by providing critical insights into genetic compatibility and potential responses to immunosuppressive therapies. Market analysis suggests that the demand for personalized diagnostic solutions is on the rise, as healthcare providers seek to optimize transplant outcomes and minimize complications. This trend is likely to continue, further driving innovation and investment in the molecular diagnostics sector.

### Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases, such as diabetes and hypertension, is driving the demand for organ transplants. As these conditions lead to organ failure, the need for effective transplant solutions becomes paramount. The Molecular Diagnostics for Transplant Market is witnessing a surge in demand for diagnostic tools that can accurately assess organ compatibility and monitor transplant success. According to recent data, the prevalence of end-stage renal disease has increased significantly, necessitating more kidney transplants. This trend underscores the importance of molecular diagnostics in ensuring better patient outcomes and optimizing transplant procedures.

### Growing Awareness of Transplantation Benefits

There is a notable increase in awareness regarding the benefits of organ transplantation, which is positively influencing the Molecular Diagnostics for Transplant Market. Educational campaigns and advocacy efforts are encouraging more individuals to consider organ donation and transplantation as viable options for treating end-stage organ failure. This heightened awareness is leading to an increase in transplant procedures, thereby driving the demand for molecular diagnostics that can facilitate better donor-recipient matching. As more patients seek transplants, the need for reliable diagnostic tools becomes increasingly critical, further propelling market growth.

### Regulatory Support for Diagnostic Innovations

Regulatory bodies are increasingly supporting innovations in the Molecular Diagnostics for Transplant Market, which is fostering a conducive environment for the development of new diagnostic tools. Streamlined approval processes and guidelines for molecular diagnostics are encouraging companies to invest in research and development. This regulatory support is crucial for bringing advanced diagnostic solutions to market more efficiently, ultimately enhancing patient care in transplantation. The presence of favorable regulations is likely to stimulate competition among diagnostic manufacturers, leading to a wider array of options for healthcare providers and patients alike.

## Future Outlook

The Molecular Diagnostics for Transplant Market is projected to grow at an 8.91% CAGR from 2025 to 2035, driven by technological advancements, increasing transplant procedures, and rising demand for personalized medicine.

**New opportunities:**

- Development of portable molecular diagnostic devices for point-of-care testing. Integration of AI algorithms for predictive analytics in transplant compatibility. Expansion of telehealth services for remote patient monitoring and diagnostics.

By 2035, the market is expected to achieve substantial growth, driven by innovation and increased adoption of molecular diagnostics.

## Segment Insights

### By Product: Reagents & Kits (Largest) vs. Instruments (Fastest-Growing)

In the Molecular Diagnostics for Transplant Market, the product segment is primarily defined by Reagents & Kits, which dominate the landscape with significant market share. These essential components facilitate various diagnostic tests and are crucial for the accuracy and reliability of transplant procedures. Instruments also play a vital role but follow closely behind as a growing segment, driven by advancements in technology and an increasing need for precision. Together, these product categories highlight the essential tools for healthcare providers in managing transplant diagnostics efficiently. Growth in this segment is substantially influenced by the rising prevalence of transplant procedures and the increasing demand for precise diagnostics. Reagents & Kits remain crucial due to their continuous innovation and development of new testing methods. Meanwhile, the Instruments segment is experiencing rapid growth as healthcare facilities invest in state-of-the-art machinery to enhance diagnostic capabilities. This trend is aided by an increased emphasis on personalized medicine and tailored treatment approaches, further fueling market expansion in this area.

Reagents & Kits (Dominant) vs. Instruments (Emerging)

Reagents & Kits are the dominant force in the Molecular Diagnostics for Transplant Market, characterized by their broad application across various tests essential for donor-recipient matching. They are the backbone of the diagnostic process, providing healthcare professionals with critical information required for transplant success. This category benefits from ongoing research and development efforts, ensuring that new kits meet evolving medical standards and regulations. On the other hand, Instruments represent an emerging segment with rapid technological advancements leading to innovative diagnostic tools. These tools enhance accuracy and workflow efficiency, driving adoption in laboratories. The synergy between high-quality reagents and cutting-edge instruments is a key trend shaping the market, emphasizing the interdependence of these two essential product categories.

### By Technology: Polymerase Chain Reaction (PCR) (Largest) vs. Sequencing (Fastest-Growing)

In the Molecular Diagnostics for Transplant Market, the Polymerase Chain Reaction (PCR) technology holds the largest market share, owing to its widespread application in pathogen detection and genetic analysis. This method is crucial for monitoring transplant rejection and has been integral in enhancing patient outcomes. On the other hand, sequencers, while currently smaller in market share, are rapidly gaining traction due to their ability to provide comprehensive genomic insights, thus supporting personalized medicine efforts in transplantation.

Technology: PCR (Dominant) vs. Sequencing (Emerging)

PCR is known for its reliability and efficiency in amplifying small segments of DNA, making it a cornerstone in the diagnostic toolkit for transplant patients. Its established presence gives it dominance in clinical and laboratory settings, where rapid results are needed for timely interventions. Sequencing, an emerging technology, is steadily transforming the landscape by offering deeper insights into the genetic makeup of both donors and recipients. The ability to identify variations and mutations through next-generation sequencing empowers clinicians to tailor immunosuppressive therapies more effectively, thus enhancing patient care and outcomes.

### By End User: Hospitals and Transplant Centers (Largest) vs. Research Laboratories & Academic Institutes (Fastest-Growing)

In the Molecular Diagnostics for Transplant Market, Hospitals and Transplant Centers hold the largest share, reflecting their critical role in organ transplant procedures and post-transplant monitoring. They leverage advanced molecular diagnostics technologies to ensure compatibility and monitor transplant success rates, which caters to a substantial patient population. Research Laboratories and Academic Institutes, on the other hand, are emerging as a significant player in this market, focusing on innovative research and development of novel diagnostic techniques that enhance patient outcomes and facilitate better understanding of transplant immunology.

End Users: Hospitals and Transplant Centers (Dominant) vs. Research Laboratories & Academic Institutes (Emerging)

Hospitals and Transplant Centers are pivotal in the Molecular Diagnostics for Transplant Market, serving as the primary end-users. Their dominance stems from the ongoing demand for reliable diagnostic tools that are essential for successful organ transplants. These centers utilize molecular diagnostics to screen donors and recipients, ensuring tissue compatibility and mitigating the risk of organ rejection. Conversely, Research Laboratories and Academic Institutes are recognized as emerging entities within this sector. They are increasingly focused on developing cutting-edge diagnostic solutions and expanding the understanding of transplant-related complications. This growth is driven by their commitment to innovation and the need for personalized medicine approaches, making them vital contributors to advancing the field.

## Regional Market Share Analysis

### North America : Leading Innovation and Adoption

North America is the largest market for molecular diagnostics in transplantation, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high R&D investments, and a growing prevalence of transplant procedures. Regulatory support from agencies like the FDA further drives innovation and adoption of new technologies, enhancing patient outcomes and operational efficiencies. The United States is the primary contributor, with significant market players such as Thermo Fisher Scientific, Abbott Laboratories, and Illumina leading the charge. Canada also plays a vital role, focusing on improving transplant success rates through molecular diagnostics. The competitive landscape is characterized by continuous innovation and strategic partnerships among key players, ensuring a robust market presence.

### Europe : Emerging Regulatory Frameworks

Europe is the second-largest market for molecular diagnostics in transplantation, accounting for approximately 30% of the global market. The region is witnessing growth driven by stringent regulatory frameworks and increasing demand for personalized medicine. Countries like Germany and the UK are at the forefront, implementing policies that encourage the adoption of advanced diagnostic technologies, thereby enhancing patient care and treatment outcomes. Germany leads the market, supported by a strong healthcare system and significant investments in biotechnology. The UK follows closely, with a focus on integrating molecular diagnostics into routine clinical practice. Key players such as Roche Diagnostics and Qiagen are actively involved in this landscape, contributing to a competitive environment that fosters innovation and collaboration among stakeholders.

### Asia-Pacific : Rapid Growth and Adoption

Asia-Pacific is rapidly emerging as a significant player in the molecular diagnostics for transplantation market, holding approximately 20% of the global share. The region's growth is fueled by increasing healthcare expenditure, rising awareness of transplant procedures, and advancements in technology. Countries like China and India are leading this growth, supported by government initiatives aimed at improving healthcare access and quality. China is the largest market in the region, driven by a vast population and increasing demand for organ transplants. India is also witnessing a surge in the adoption of molecular diagnostics, with a growing number of healthcare facilities investing in advanced technologies. The competitive landscape includes key players like Hologic and Becton Dickinson, who are expanding their presence through strategic partnerships and collaborations.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region represents an emerging market for molecular diagnostics in transplantation, holding approximately 5% of the global market share. The growth is primarily driven by increasing healthcare investments, rising prevalence of chronic diseases, and a growing focus on improving healthcare infrastructure. Countries like South Africa and the UAE are leading the way, with initiatives aimed at enhancing transplant success rates through advanced diagnostic technologies. South Africa is the largest market in the region, supported by a well-established healthcare system and increasing public awareness of organ donation. The UAE is also making strides, with government support for healthcare innovation. The competitive landscape is characterized by a mix of local and international players, creating opportunities for growth and collaboration in the molecular diagnostics space.

## Competitive Benchmarking

Major market players are spending a lot of money on R&D to increase their product lines, which will help the molecular diagnostics for transplant market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the molecular diagnostics for transplant industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
Thermo Fisher Scientific Inc. (US) specializes in various biotechnology products such as analytical instruments, laboratory supply chain programs and e-commerce, laboratory equipment, lab services, and specialty diagnostics. The company helps its customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to the market, and increase the laboratory's productivity.
In September the company announced a new addition to its transplant diagnostics portfolio (a rapid next-generation sequencing assay that will provide high-resolution data in five hours). This new product enabled transplant laboratories to characterize samples better and bring speed and confidence to the transplant laboratory.

## Recent News & Developments

**October 2022** Eurobio Scientific (France) acquired Genome Diagnostics B.V. (Netherlands) for the commercial portfolio of human leukocyte antigen (HLA) diagnostics to assess the compatibility between donors and recipients for organ and marrow transplants.

**February 2022** Bio-Techne Corporation (US) entered into an agreement with Thermo Fisher Scientific, Inc. (US) in order to develop and commercialize the ExoTRU Kidney Transplant Rejection Test.

**In September 2021** Thermo Fisher Scientific Inc. (US) announced a new addition to its transplant diagnostics portfolio (a rapid next-generation sequencing assay that will provide high-resolution data in five hours). This new product enabled transplant laboratories to characterize samples better and bring speed and confidence to the transplant laboratory.

## Report Scope

| MARKET SIZE 2024 | 0.8422(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.9172(USD Billion) |
| MARKET SIZE 2035 | 2.153(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.91% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Thermo Fisher Scientific (US), Roche Diagnostics (CH), Abbott Laboratories (US), Qiagen (DE), Hologic (US), Becton Dickinson (US), Genomic Health (US), Myriad Genetics (US), Illumina (US) |
| Segments Covered | Product, Technology, End User, Region |
| Key Market Opportunities | Advancements in personalized medicine enhance demand for Molecular Diagnostics for Transplant Market solutions. |
| Key Market Dynamics | Technological advancements in molecular diagnostics enhance transplant compatibility assessments, driving market growth and competitive dynamics. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for the Molecular Diagnostics for Transplant Market in 2035?**
A: The projected market valuation for 2035 is 2.153 USD Billion.

**Q: What was the market valuation for the Molecular Diagnostics for Transplant Market in 2024?**
A: The overall market valuation was 0.8422 USD Billion in 2024.

**Q: What is the expected CAGR for the Molecular Diagnostics for Transplant Market from 2025 to 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 8.91%.

**Q: Which product segment is anticipated to show the highest growth in the Molecular Diagnostics for Transplant Market?**
A: The Reagents & Kits segment is projected to grow from 0.42 to 1.05 USD Billion.

**Q: How does the market for Instruments in Molecular Diagnostics for Transplant compare between 2024 and 2035?**
A: The Instruments segment is expected to increase from 0.25 to 0.6 USD Billion.

**Q: What are the key technologies driving the Molecular Diagnostics for Transplant Market?**
A: Key technologies include Polymerase Chain Reaction (PCR) and Sequencing, with PCR projected to grow from 0.3362 to 0.8455 USD Billion.

**Q: Which end-user segment is likely to dominate the Molecular Diagnostics for Transplant Market by 2035?**
A: Hospitals and Transplant Centers are expected to dominate, growing from 0.50576 to 1.3095 USD Billion.

**Q: What role do major companies like Thermo Fisher Scientific and Roche Diagnostics play in the market?**
A: Companies such as Thermo Fisher Scientific and Roche Diagnostics are key players, influencing market trends and innovations.

**Q: What is the expected growth for Research Laboratories & Academic Institutes in the Molecular Diagnostics for Transplant Market?**
A: This segment is projected to grow from 0.16866 to 0.4365 USD Billion.

**Q: How does the Others segment in the Technology category perform in the Molecular Diagnostics for Transplant Market?**
A: The Others segment is expected to increase from 0.0857 to 0.2516 USD Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/molecular-diagnostics-for-transplant-market-11826*